Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Can-Fite BioPharma Ltd. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 7 | 9 | +2 |
| Shares | 54.6K | 67.7K | +13.0K (+23.8%) |
| Value | $167.8K | $179.2K | +$11.4K (+6.8%) |
New holders (2)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 12,047 | $31.9K | 0.00% |
| JPMorgan Chase & Co | 460 | $1.22K | 0.00% |
Sold out (0)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q2 2023 and filed for Q3 2023 without it.
None.